Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.25 USD

6.25
386,529

-0.27 (-4.14%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $6.26 +0.01 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (159 out of 248)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.

AngioDynamics (ANGO) Upgraded to Strong Buy: What Does It Mean for the Stock?

AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here's Why You Should Add AngioDynamics to Your Portfolio Now

Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.

AngioDynamics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in AngioDynamics.

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.

AngioDynamics (ANGO) in Focus: Stock Moves 6.2% Higher

AngioDynamics (ANGO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

AngioDynamics (ANGO) Tops Q1 Earnings and Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 6.95%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics Unveils Auryon Atherectomy System for PAD

AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.

Why Is AngioDynamics (ANGO) Down 1.3% Since Last Earnings Report?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for August 5th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for August 3rd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates

AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.

AngioDynamics (ANGO) Reports Q4 Loss, Lags Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of -20.00% and -6.28%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Buy These 5 Low Leverage Stocks to Avoid Debt-Related Risk

Exorbitant debt financing might even cause a corporation's bankruptcy in the worst-case scenario.

Here's Why You Should Add AngioDynamics to Your Portfolio

AngioDynamics (ANGO) continues to benefit from strategic buyouts and strong product portfolio.

AngioDynamics (ANGO) Down 1.6% Since Last Earnings Report: Can It Rebound?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis

Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.

AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.

AngioDynamics (ANGO) Beats Q3 Earnings and Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 1.98%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics (ANGO) Upgraded to Buy: Here's What You Should Know

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AngioDynamics (ANGO) Down 10.4% Since Last Earnings Report: Can It Rebound?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to AngioDynamics Stock Now

AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.